Matricelf Ltd
TASE:MTLF
Matricelf Ltd
Other Items
Matricelf Ltd
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Other Items
₪9.9m
|
CAGR 3-Years
635%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Other Items
$8k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-46%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Other Items
$11.5m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Other Items
$61.8m
|
CAGR 3-Years
261%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Other Items
$7.2m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
17%
|
|
Matricelf Ltd
Glance View
Matricelf Ltd. engages in research and development of technology in the field of regenerative medicine. The firm operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The firm focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinson’s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.
See Also
What is Matricelf Ltd's Other Items?
Other Items
9.9m
ILS
Based on the financial report for Dec 31, 2024, Matricelf Ltd's Other Items amounts to 9.9m ILS.
What is Matricelf Ltd's Other Items growth rate?
Other Items CAGR 3Y
635%
Over the last year, the Other Items growth was -11%. The average annual Other Items growth rates for Matricelf Ltd have been 635% over the past three years .
